William, any decisive move will need institutional not individual investors. Some time ago a poster mentioned that Murphy used to work with McCamant. At that time I believed that fact alone, increased the probability Murphy would also recomend XOMA. Murphys letter and recomendation are important but the fact that he manages mutual funds is more important.
The trauma data is obviously available to XOMA. Some info on the phase II trials is on XOMA's site. I also wonder what is so important that will now be said for the first time on Nov. 6- or 7. If it is so important I think some announcement would have already been made to shareholders. However the same could have been said about CORR which is up on pesentation not FDA news.
I have a sizable position in XOMA and feel quite comfortable with it. It is too bad the general market has reached such high levels, as this increases the risk beyond that of just holding XOMA.
If and when XOMA moves up I believe many will use such a move to lighten up. Others will use the breakout to buy. I will not be a direct seller in what I think may be the inital move. By then options should be available and I will probably sell calls and to the extent they are exercised also sell puts.
I have sold calls on ICOS, CORR, SEPR, LSI, AMAT, ADBE, ARRS and many other stocks and must admit in almost all cases would have been better off just holding the stock. In most if not all cases I had sold puts on the stocks originally, so I am not crying. My point is when we all look back on XOMA when an if it finally begins to rise, selling part or selling calls may be the worst thing we could do. |
